Literature DB >> 29453870

Comparison of Melanocyte Density Counts in Topical Imiquimod-Treated Skin Surrounding Lentigo Maligna vs Control Biopsy Specimens.

Shadai Flores1, Nathan J Luby1, Glen M Bowen1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29453870      PMCID: PMC5876898          DOI: 10.1001/jamadermatol.2017.5632

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  5 in total

1.  Prognostic markers in lentigo maligna patients treated with imiquimod cream: A long-term follow-up study.

Authors:  Mirja Gautschi; Patrick A Oberholzer; Marc Baumgartner; Karolina Gadaldi; Nikhil Yawalkar; Robert E Hunger
Journal:  J Am Acad Dermatol       Date:  2015-10-23       Impact factor: 11.527

2.  Immunohistochemical staining with Melan-A of uninvolved sun-damaged skin shows features characteristic of lentigo maligna.

Authors:  Anneli R Bowen; Betsy N Perry Thacker; David E Goldgar; Glen M Bowen
Journal:  Dermatol Surg       Date:  2011-03-29       Impact factor: 3.398

3.  A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions.

Authors:  Mark A Hyde; Michael L Hadley; Payam Tristani-Firouzi; David Goldgar; Glen M Bowen
Journal:  Arch Dermatol       Date:  2012-05

4.  A model for lentigo maligna recurrence using melanocyte count as a predictive marker based upon logistic regression analysis of a blinded retrospective review.

Authors:  Mark Gorman; Muhammad A A Khan; Paul C D Johnson; Andrew Hart; Bipin Mathew
Journal:  J Plast Reconstr Aesthet Surg       Date:  2014-06-04       Impact factor: 2.740

5.  Staged excision for lentigo maligna and lentigo maligna melanoma: A retrospective analysis of 117 cases.

Authors:  Carole Hazan; Stephen W Dusza; Ruby Delgado; Klaus J Busam; Allan C Halpern; Kishwer S Nehal
Journal:  J Am Acad Dermatol       Date:  2007-10-29       Impact factor: 11.527

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.